Investor & Media Relations
We discover and develop medicines to defeat neurodegeneration.
The science is breaking open and the time is right for an ambitious and rigorous effort to address Alzheimer’s disease, Parkinson’s disease, ALS and other neurodegenerative diseases. We are applying deep scientific and drug development expertise to discover effective molecular therapeutics and have engineered a proprietary technology to deliver biologic therapeutics to the brain.
With a team of experienced and passionately dedicated scientists and drug developers, we believe we can succeed in meaningfully improving the lives of patients and their families.
View detailed list of firms and analysts.
View, download, and share all SEC Filing documents.
View, download, and share Corporate Governance documents.
Denali Therapeutics Inc. was incorporated in Delaware in October 2013
Denali is headquartered in South San Francisco, CA.
Denali's fiscal year ends December 31st
Ernst & Young LLP is Denali's independent registered public accounting firm
Denali is traded on the NASDAQ Global Select Stock Market under the ticker symbol "DNLI"
Denali initial public offering occurred on December 8, 2017
American Stock Transfer & Trust Company
(800) 937-5449 (Toll-free)
(718) 921-8124 (International)
American Stock Transfer & Trust Company Operations Center
6201 15th Avenue
Brooklyn, NY 11219
Electronic copies of our Annual Report and other periodic reports are available on this website. If you would like to request paper copies of the Annual Report or other periodic reports, send your request in writing to:
Denali Therapeutics Inc.
Attn: Corporate Secretary
151 Oyster Point Blvd
South San Francisco, CA 94080
Sign up for email alerts
Stay in the loop with updates on the latest Denali news delivered right to your inbox
Required fields denoted by an asterisk (*).